I’ve always longed to be a part of the movement to legalize shrooms for medicinal purposes one day. And now, the dream is closer than ever! I never realized how close we were in research and how far forward we are in the process of doing so. This makes me really happy 🙂 Thank you psychedelic society!
Psilocybin, the psychoactive component in magic mushrooms, is proving a prodigious treatment for anxiety, depression, addiction and one study even found it may lead to neurogenesis (the regrowth of brain cells). Dr. David E. Nichols, one of the co-founders of the Heffter Research Institute, explains the steps it will take for medicinal psilocybin to be legalized.
Psilocybin has been recently tested for many purposes:
- Dr. Charles Grob at UCLA Harbor Medical Center: treatment of 12 terminal cancer patients who suffered from anxiety and depression. They were treated with a program of therapy that included psilocybin. Participants showed a significant reduction in anxiety at one and three months after treatment, with no significant adverse events.
- Dr. Roland Griffiths (Johns Hopkins University) and Dr. Stephen Ross (NYU): two additional studies were begun using psilocybin to treat anxiety and depression in cancer patients
- Dr. Michael Bogenschutz at University of New Mexico (UNM): a study of psilocybin-assisted therapy in a pilot study of 10 volunteers with alcohol dependence. Drinking decreased significantly beginning in the second month of treatment, after psilocybin was administered, and improvement remained significant for an additional six months of follow-up. There were strong correlations between the intensity of the experience in the first psilocybin session and clinical improvement following the session.
- Dr. Matthew Johnson at Johns Hopkins University: a pilot study administering psilocybin within a 15-week smoking cessation treatment. Participants were 15 healthy smokers with a mean of six previous lifetime quit attempts who were smoking an average of 19 cigarettes per day for 31 years. Measures of smoking behavior showed that 12 of the 15 participants (80%) were no longer smoking at six-month follow-up. This smoking cessation rate substantially exceeds rates commonly reported for other types of therapies (typically less than 35%). These findings suggest that psilocybin may be a useful and potentially efficacious adjunct to current smoking cessation treatment approaches, and warrant a follow-up clinical trial. Results also illustrate a framework for research on the efficacy and mechanisms of psychedelic-facilitated addiction treatment.
Currently, we are in Phase 2 of 3 in trying to legalize magic mushrooms, where we have to show statistical significance that it is safe and that it can treat the specified condition (in this case, it is anxiety and depression). However, Phase 3 is going to be a hard one and may take awhile to complete the studies.
There is no drug company or government support for these studies.
For the full article, click here